Antique has initiated coverage on Max Healthcare Institute Ltd. with a 'Hold' rating and a target price of ₹1,170, implying an upside of about 8%. The brokerage maintains a cautious stance despite the company's ambitious expansion plans, citing valuation concerns after the stock's strong run-up. Max Healthcare operates more than 6,100 beds across 21 healthcare facilities and plans to increase capacity by about 66% to around 10,200 beds by FY30. Nearly 88% of the expansion will come through brownfield projects and asset-light operations and management contracts.
Max Healthcare is embarking on an ambitious expansion program to significantly increase its hospital capacity. According to reports from Moneycontrol, the company is planning to add 4,000 beds over the next four years. This substantial capacity addition represents a major growth initiative for the healthcare provider and provides good growth visibility for the company's future operations. The expansion timeline spans four years, indicating a phased approach to scaling the healthcare provider's hospital network.
Despite the 'Hold' rating, Max Healthcare shows strong financial projections with revenue, EBITDA and PAT CAGR of 19%, 21% and 19% respectively over FY26-28. As per Antique's analysis, the company's current performance metrics are described as industry leading. The capacity additions are expected to test these established performance benchmarks as the company scales its operations significantly, potentially challenging the healthcare provider's ability to maintain its industry-leading standards. The brokerage expects demand to remain healthy, supported by rising insurance penetration, Ayushman Bharat and PM-JAY, growing medical tourism, and continued market share gains by organised hospital chains.
According to Antique's sector analysis, India's listed hospital chains are entering a multi-year expansion phase backed by strong healthcare demand, higher insurance penetration and capacity additions. The brokerage expects the healthcare delivery market to grow at a 10-12% CAGR to ₹12 lakh crore over FY25-FY30, with private providers increasing their share of treatments to around 69% by FY30 from 64% in FY20. The sector outlook remains positive despite concerns around hospital overcapacity being overstated, with revised building height norms, Competition Commission of India's order on integrated healthcare delivery models, and revised CGHS tariffs supporting the sector's growth trajectory.
